Methotrexate and Metformin in Rheumatoid Arthritis Patients

Last updated: June 20, 2024
Sponsor: University Hospital, Bordeaux
Overall Status: Active - Not Recruiting

Phase

2

Condition

Joint Injuries

Rheumatoid Arthritis

Treatment

Placebo

Methotrexate treatment

Metformin treatment

Clinical Study ID

NCT04196868
CHUBX 2016/44
  • Ages > 18
  • All Genders

Study Summary

Methotrexate (MTX) is the anchor drug for patients with rheumatoid arthritis (RA). Despite its marked efficacy and acceptable side effect profile, about 1/3 of patients failed to reach RA remission. Metformin is the first-line therapy for type 2 diabetes. Its antioxidative and anti-inflammatory properties make it a good candidate for the treatment of inflammatory diseases such as rheumatoid arthritis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients aged over 18 years old,

  • Patient affected by RA according to American College of Rheumatology (ACR) 2010criteria

  • DAS28-ESR > 3.2

  • Methotrexate naïve patients, or without any methotrexate intake for more than sixmonths.

  • Men who accept to take active contraception during the study and during six monthsafter the end of the Methotrexate treatment. Partner of patient will be informed ofteratogenicity of MTX and will be advised to be on effective contraceptives for allthe study duration.

OR

  • Women with a negative test of β-human chorionic gonadotropin (HCG) who accept totake active contraception during the study and during six months after the end ofthe Methotrexate treatment

  • Patients without any Metformin previous therapy.

  • Being affiliated to a health insurance system

  • Having signed an informed consent form (later than the day of inclusion and beforeany examination required by the research)

Exclusion

Exclusion Criteria:

  • Patient who present contraindications to treatment with Methotrexate or Metformin

  • Patient with type 1 or type 2 diabetes

  • Patient with daily corticosteroid treatment at a dosage ≥ 15 mg/day within fourweeks before the inclusion

  • History of allergy or intolerance to biguanide

  • Presence of anemia (hemoglobin < 80 g/l), neutropenia (neutrophils count < 1500mm3), lymphopenia (lymphocytes count < 750 mm3), thrombopenia (platelets < 100 000/mm3) or bone marrow hypoplasia.

  • Renal insufficiency with clearance < 50 ml/mn

  • Decompensated heart failure

  • Uncontrolled heart history

  • Severe respiratory insufficiency

  • Hepatic insufficiency, or bilirubin level upper than 5mg/dl (85,5 µmol/l), oraspartate transaminase (ASAT) / alanine aminotransferase (ALAT) more than twice thestandard level.

  • Acute or chronic infection, such as tuberculosis or HIV

  • Critical ischemia of the lower limbs

  • Recent stroke

  • Patient with pleural effusion, or ascites

  • Patient with stomatitis, mouth ulcers, or active gastrointestinal ulcer.

  • Patient with alcohol intoxication

  • B12 Vitamin deficiency

  • Patient performing or planning to perform a long-fasting period

  • Pregnant or breastfeeding women

  • Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of theirliberty by a judicial or administrative decision, minors, persons of legal age whoare the object of a legal protection measure or unable to express their consent).

Study Design

Total Participants: 128
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 2
Study Start date:
December 03, 2020
Estimated Completion Date:
June 30, 2026

Study Description

Methotrexate is usually the first-line disease modifying antirheumatic drugs (DMARD) for the treatment of RA. The main goal of its treatment is to reach disease remission but, despite its good efficacy, 1/3 of patients failed to achieve it. This could lead to the introduction of a biologic therapy which is more expensive and exposes the patient to a greater infection risk. Neutrophils through expulsion of neutrophil extracellular traps (NETs), were found to be important in RA pathogenesis (source of anti-citrullinated protein antibodies, activation of fibroblast-like synoviocytes...). The formation of NETs is reactive oxygen species (ROS) dependent, while metformin can selectivity inhibit mitochondrial respiratory chain complex I and decrease NADPH oxidase activity, thus leading to a decrease in ROS production.

Metformin is the first-line therapy for type 2 diabetes. Recently, a study presented its potential impact in the treatment of systemic lupus erythematosus according to its metabolic properties and the inhibition of NETosis.

The aim of this study is to compare the efficacy of Methotrexate/Metformin vs. Methotrexate alone on the decrease of RA activity in MTX-naive patients, after 6 months of treatment.

Connect with a study center

  • CH de la Côte Basque - service de rhumatologie

    Bayonne,
    France

    Site Not Available

  • CHU de Bordeaux - service de rhumatologie

    Bordeaux,
    France

    Site Not Available

  • CHU de Brest - service de rhumatologie

    Brest,
    France

    Site Not Available

  • CH de Cahors - service de rhumatologie

    Cahors,
    France

    Site Not Available

  • Clinique de l'Infirmerie protestante de Lyon - service de rhumatologie

    Caluire-et-Cuire,
    France

    Site Not Available

  • CHD de Vendée - service de rhumatologie

    La Roche-sur-Yon,
    France

    Site Not Available

  • CH du Mans - service de rhumatologie

    Le Mans,
    France

    Site Not Available

  • CH de Libourne - service de rhumatologie

    Libourne,
    France

    Site Not Available

  • CHU de Limoges - service de rhumatologie

    Limoges,
    France

    Site Not Available

  • CHU de Montpellier - service de rhumatologie

    Montpellier,
    France

    Site Not Available

  • CH des Pays de Morlaix - service de rhumatologie

    Morlaix,
    France

    Site Not Available

  • CHR Orléans la Source - service de rhumatologie

    Orléans,
    France

    Site Not Available

  • CH de Pau - service de rhumatologie

    Pau,
    France

    Site Not Available

  • CHU de Toulouse - service de rhumatolgie

    Toulouse,
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.